Transcription profiling of human acute myeloid leukemia samples from subjects younger than 60 years old

ABSTRACT: The pretreatment karyotype of leukemic blasts is currently the key determinant in therapy decision-making in acute myeloid leukemia (AML). However, approximately fifty percent of AML patients, often carrying a normal karyotype, are currently unclassifiable based these established methods. Gene expression profiling has proven to be valuable for risk stratification of AML. The gene expression profiles of AML samples of two independent cohorts (n=247 and n=214) were determined using Affymetrix U133Plus2.0 GeneChips: all Samples (starting with 'amlrrays 2') below 4000 are in the training cohort; all Samples higher than 4000 are in the validation cohort. Data analyses were carried out to discover and predict prognostically relevant subtypes in AML (<60 years) based on their gene expression sig

ORGANISM(S): Homo sapiens

SUBMITTER: Roel Verhaak 

PROVIDER: E-GEOD-6891 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress